Document:

EX-10.1

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of February 24, 2006, by and
between Corinthian Colleges, Inc., a Delaware corporation (the “Company”), and David G. Moore
(“Employee”).

WITNESSETH:

WHEREAS, the Company and Employee desire to enter into this Agreement to assure the Company of the
continuing and exclusive service of Employee and to set forth the terms and conditions of
Employee’s employment with the Company.

AGREEMENT:

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, the parties
agree as follows:

	1.	 	TERM. The Company agrees to employ Employee and Employee hereby accepts such employment, in
accordance with the terms of this Agreement, commencing on the date of this Agreement (the
“Effective Date”) and continuing for a period of two (2) years hereafter (the “Term”), subject
to earlier termination under Section 5 or extension of such term as described in the next
sentence. Unless either party has given advanced written notice to the other party that the
Term shall not be extended (or further extended, as the case may be), then (1) upon the first
anniversary of the Effective Date the Term shall automatically be extended by an additional
year (such that the Term shall be scheduled to terminate on the third anniversary of the
Effective Date), and (2) upon the second and each successive anniversary of the Effective Date
the Term shall automatically be extended by an additional year; provided, however,
that in no event shall the Term exceed a period of five (5) years. Provision of notice that
this Agreement shall not be extended or further extended, as the case may be, shall not
constitute breach of this Agreement or entitle the Employee to any benefits described in
Section 5.

	2.	 	SERVICES AND EXCLUSIVITY OF SERVICES. During the Term of this Agreement, Employee shall
devote Employee’s full business time, energy and ability exclusively to the business, affairs
and interests of the Company and matters related thereto, shall use Employee’s best efforts
and abilities to promote the Company’s interests and shall perform the services contemplated
by this Agreement in accordance with policies established by and under the direction of the
Board of Directors of the Company (the “Board”).

Employee shall not, directly or indirectly, during the term of this Agreement render services to
any other person or firm for compensation or engage in any activity competitive with or adverse
to the Company’s business. Employee may serve as a director or in any other capacity of any
business enterprise or any nonprofit or governmental entity or trade association, provided in
each case that such service is approved by the Board. Notwithstanding the foregoing, Employee
may make and manage personal business investments of Employee’s choice and serve in any capacity
with any civic, educational or charitable organization (other than as a director of such
organization, approval for which may be sought under the immediately preceding sentence of this
Section 2) without seeking the approval of the Board, provided that such activities and services
do not interfere or conflict with the performance of the duties hereunder or create any conflict
of interest with such duties.

	3.	 	DUTIES AND RESPONSIBILITIES. Employee shall serve as Chairman of the Board of the Company for
the Term of this Agreement. In the performance of Employee’s duties, Employee shall report
directly to the Board of the Company and shall be subject to the direction of the Board and to
such limits on Employee’s authority as the Board may from time to time impose. During the
term of this Agreement, Employee shall be based at the Company’s principal executive offices
in Orange County, California. Employee agrees to observe and comply with the rules and
regulations of the Company and agrees to carry out and perform orders, directions and policies
of the Company and its Board as they may be, from time to time, stated either orally or in
writing. The Company agrees that the duties which may be assigned to Employee shall be usual
and customary duties of the office(s) or position(s) to which Employee may from time to time
be appointed or elected and shall not be inconsistent with the provisions of the charter
documents of the Company or applicable law. Employee shall have such corporate power and
authority as shall reasonably be required to enable Employee to perform the duties required in
any office that may be held.

	4.	 	COMPENSATION.

(a) Base Compensation. During the term of this Agreement, the Company agrees to pay Employee a
base salary at the annual rate of not less than [INSERT CURRENT BASE SALARY], payable in
accordance with the Company’s practices in effect from time to time (the “Base Salary”).

(b) Additional Benefits. Employee shall also be entitled to all rights and benefits for which
Employee is otherwise eligible under any bonus plan, incentive agreement (including stock
options and/or other awards granted pursuant to the Company’s 1998 Performance Award Plan, the
Company’s 2003 Performance Award Plan and the Company’s 2004 New Hire Plan (hereinafter the
“Equity Award Plans”)), participation or extra compensation plan, pension plan, profit-sharing
plan, life, medical, dental, disability, or insurance plan (including, except as otherwise
prohibited therein, the Company’s Employee Stock Purchase Plan) or policy or other plan or
benefit that the Company may provide for Employee or (provided Employee is eligible to
participate therein) for Peer Employees (defined as the original founders of the Company) or for
employees of the Company generally, as from time to time in effect, during the term of this
Agreement (collectively, all of the above shall be referred to as the “Additional Benefits”).

(c) Periodic Review. The Compensation Committee of the Board shall review Employee’s Base
Salary and Additional Benefits then being paid to Employee not less frequently than every twelve
months. Following such review, the Company may in its discretion increase (but shall not be
required to increase) the Base Salary or any other benefits, but may not decrease the Base
Salary during the time Employee serves as Chairman of the Board, President and Chief Executive
Officer; provided, however, that if the Company undertakes any generalized salary
reductions of employees of the Company, the Company may reduce Employee’s Base Salary by a
percentage equal to the percentage base salary reductions effected for all other Peer Employees
of the Company.

(d) Perquisites. Employee shall be entitled to not less than three weeks paid vacation each
twelve-month period (or such larger amount of paid vacation as is generally granted to employees
of the Company based on time of service with the Company), which shall accrue on a pro rata
basis from the Effective Date of this Agreement. Vacation time will continue to accrue so long
as Employee’s total accrued vacation does not exceed two times (2x) the then-current rate of
annual vacation accrual of the Employee (the “Vacation Accrual Cap”). Should Employee’s accrued
vacation time reach the Vacation Accrual Cap, Employee will cease to accrue additional vacation
until Employee’s accrued vacation time falls below the Vacation Accrual Cap. Except with
respect to the rate of vacation accrual set forth above, all vacation time shall be subject to
the plans, policies, programs and practices as in effect generally with respect to other Peer
Employees of the Company.

	5.	 	TERMINATION. This Agreement and all obligations hereunder (except the obligations contained
in Sections 8, 9, 10 and 11 (Confidential Information, Non-Competition, Non Solicitation of
Employees and Indemnity) which shall survive any termination hereunder) shall terminate upon
the earliest to occur of any of the following:

(a) Voluntary Termination. Subject to Section 5(e) below, the voluntary termination by Employee
or retirement from the Company in accordance with the normal retirement policies of the Company.

(b) Death or Disability of Employee. Employee’s employment shall be terminated upon the death or
Disability (as defined below) of Employee. In such instance, except as set forth below, all
obligations hereunder to Employee (or Employee’s heirs or legal representatives) shall cease,
other than for payment of the sum of (A) Employee’s Base Salary through the date of termination
to the extent not theretofore paid, (B) any bonus or other cash compensation agreement for the
pro rata amount earned through the date of termination, (C) compensation previously deferred by
Employee (together with any accrued interest or earnings thereon), and (D) any accrued vacation
pay, in each case to the extent not theretofore paid (the sum of the amounts described in
clauses (A), (B), (C) and (D) shall be hereinafter referred to as the “Accrued Obligations”),
which shall be paid to Employee or Employee’s estate or beneficiary, as applicable, in a lump
sum in cash within 30 days after the date of termination or any earlier time required by
applicable law. For the purposes of this Agreement, Disability shall mean the absence of
Employee performing Employee’s duties with the Company on a full-time basis for a period of six
months, as a result of incapacity due to mental or physical illness which is determined to be
total and permanent by a physician selected by the Company or its insurers and acceptable to
Employee or Employee’s legal representative (such agreement as to acceptability not to be
withheld unreasonably). The termination of this Agreement due to the death or Disability of
Employee shall have no effect on the rights and obligations of Employee (or his personal
representative or beneficiary, as the case may be) with respect to stock options or other rights
granted under the Company’s Equity Award Plans, as amended, or the Company’s Employee Stock
Purchase Plan, or any subsequent employee benefit or equity compensation plan adopted by the
Company, all of which rights and obligations shall be governed solely and exclusively by the
applicable terms and conditions of such plans and the agreements issued thereunder.

(c) Cause. The Company may terminate Employee’s employment and all of Employee’s rights to
receive Base Salary and any Additional Benefits hereunder for Cause. For purposes of this
Agreement, the term “Cause” shall be defined as any of the following; provided, however,
that the Company must determine the presence of such Cause in good faith:

(i) Willful misconduct by Employee which materially and demonstrably injures the Company,
including (1) Employee’s material breach of any material duties and responsibilities under
this Agreement (other than as a result of incapacity due to Employee’s Disability), (2)
Employee’s commission of a material act of fraud upon the Company or (3) Employee’s
immoderate use of alcoholic beverages or narcotics or other substance abuse;

(ii) Employee willfully engaging in conduct specifically prohibited by the Company’s written
policies, including, without limitation, unlawful harassment of any other Company employee.

(iii) Employee’s conviction by, or entry of a plea of guilty or nolo contendere in, a court
of competent and final jurisdiction for a felony or any crime which materially adversely
affects the Company and/or its reputation in the community and which involves moral
turpitude or is punishable by imprisonment in the jurisdiction involved.

For purposes of this Section 5, no act or failure to act on the part of Employee shall be
considered “willful” unless done, or omitted to be done, by Employee in bad faith and
without reasonable belief by Employee that such action or omission was in the best interest
of the Company. Notwithstanding the foregoing, Employee shall not be terminated for Cause
pursuant to clauses (i), (ii) and (iii) of this Section 5(c) unless and until Employee has
received notice of a proposed termination for Cause and Employee has had an opportunity to
be heard before at least a majority of members of the Board.

(d) Without Cause. Notwithstanding any other provision of this Section 5, the Company shall
have the right to terminate Employee’s employment with the Company without Cause at any time,
but in the event of such termination without Cause, Employee shall be entitled to receive a lump
sum payment equal to the following: (A) two times (2x) the value of Employee’s Base Salary
provided under this Agreement for the most recent twelve (12) month period prior to the date of
such termination, plus (B) two times (2x) the average annual bonus paid or payable under any
bonus plan or agreement between the Company and the Employee for the most recent two (2) full
fiscal years (determined by annualizing the bonus paid or payable with respect to any partial
fiscal year) (the “Lump Sum Payment”). Such Lump Sum Payment to Employee shall be paid to
Employee within 30 days of the date of such termination.

(e) Good Reason. Employee’s employment may be terminated at any time by Employee for Good
Reason. Regardless of whether a resignation occurs prior to, coincident with or after a “Change
in Control,” Good Reason” shall mean any one or more of the following:

(i) The material failure by the Company to fulfil its obligations under this Agreement, to
the extent not remedied in a reasonable period of time after the receipt of written notice
by the Employee specifying the material failure by the Company. Any reduction or attempted
reduction by the Company (to the extent such reduction is not made equally to all employees
of a substantially equal level or position) in Employee’s Base Salary as in effect on the
date hereof or as the same may be increased from time-to-time or the taking of any action by
the Company that would substantially diminish the aggregate value of Employee’s
compensation, including any bonus, incentive or other compensation awards, retirement
benefits and other fringe benefits from the levels in effect prior to the date hereof is
deemed material.

(ii) the reassignment of Employee to a position that is not an executive officer level
position or the assignment of duties to Employee that are not consistent with such position.

(iii) The Company’s requiring Employee to be based at any office or location which increases
the distance from Employee’s home to the office or location by more than 30 miles from the
distance in effect at the Effective Date of this Agreement, unless the Company’s corporate
headquarters moves to another location and all Peer Employees (including the Employee) are
required to report to such new location.

If Employee terminates his employment with the Company for Good Reason, then Employee shall
be entitled to receive a Lump Sum Payment equal to that which would be paid to Employee
under Section 5(d) hereof.

	6.	 	BUSINESS EXPENSES. During the Term of this Agreement, to the extent that such expenditures
satisfy the criteria under the Internal Revenue Code for deductibility by the Company (whether
or not fully deductible by the Company) for federal income tax purposes as ordinary and
necessary business expenses, the Company shall reimburse Employee promptly for reasonable
business expenditures, including travel, entertainment, parking, business meetings, and
professional dues, made and substantiated in accordance with the reasonable policies,
practices and procedures established from time to time by the Company generally with respect
to other Peer Employees and incurred in the pursuit and furtherance of the Company’s business
and good will.

	7.	 	CHANGE IN CONTROL. If (A), “In Anticipation Of,” as defined below, or within twelve (12)
months after a “Change in Control” of the Company (or any successor), as defined below, the
Company involuntarily terminates Employee’s employment without Cause, or (B) within twelve
(12) months after receiving notice (which notice may be oral) of a Change in Control, the
Employee voluntarily elects to retire from full-time service to the Company, then Employee
shall receive a lump sum payment equal to the amount that would be required to be paid to
Employee as a Lump Sum Payment under Section 5(d) upon Employee’s termination other than for
Cause. If Employee voluntarily resigns following a Change in Control, the Employee may
continue to render, on a non-exclusive basis, such consulting and advisory services to the
Company as Employee may in his sole discretion accept; provided, however, that any
such consulting and advisory services, and the conditions under which they shall be performed,
shall be fully in keeping with the position or positions Employee held under this Agreement.

(a) Anything in this Agreement to the contrary notwithstanding, in the event it shall be
determined that any economic benefit, payment or distribution by the Company to or for the
benefit of the Employee, whether paid, payable, distributed or distributable pursuant to the
terms of this Agreement or otherwise (a “Payment”), would be subject to the excise tax imposed
by Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”), or any interest
or penalties with respect to such excise tax (such excise tax and any applicable interest and
penalties, collectively referred to in this Agreement as the “Excise Tax”), then the Employee
shall be entitled to receive an additional payment (a “Gross-Up-Payment”) in an amount such that
after payment by the Employee of all applicable taxes (including any interest or penalties
imposed with respect to such taxes), the Employee retains an amount equal to the amount he would
have retained had no Excise Tax been imposed upon the Payment.

(b) Subject to the provisions of Section 7(c), all determinations required to be made under this
Section 7, including whether a Gross-Up Payment is required and the amount of such Gross-Up
Payment, shall be made by the Company’s regular outside independent public accounting firm (the
“Accounting Firm”) which shall provide detailed supporting calculations both to the Company and
the Employee within 15 business days of the date of termination, if applicable, or such earlier
time as is requested by the Company. All fees and expenses of the Accounting Firm shall be
borne solely by the Company. The initial Gross-Up Payment, if any, as determined pursuant to
this Section 7, shall be paid to the Employee within 5 business days of the receipt of the
Accounting Firm’s determination. If the Accounting Firm determines that no Excise Tax is
payable by Employee, it shall furnish Employee with an opinion that he has substantial authority
not to report any Excise Tax on his federal income tax return. Any determination by the
Accounting Firm shall be binding upon the Company and the Employee. As a result of the
uncertainty in the application of Section 4999 of the Code at the time of the initial
determination by the Accounting Firm, it is possible that Gross-Up Payments that have not been
made by the Company should have been made (“Underpayment”), consistent with the calculations
required to be made under this Section 7. In the event that the Company exhausts its remedies
pursuant to Section 7(c) and the Employee thereafter is required to make a payment of any Excise
Tax, the Accounting Firm shall determine the amount of the Underpayment that has occurred and
any such Underpayment shall be promptly paid by the Company to or for the benefit of Employee.

(c) Employee shall notify the Company of any claim by the Internal Revenue Service that, if
successful, would require the payment by the Company of the Gross-Up Payment under the terms of
this Section 7. This notice shall be given as soon as practicable after the later of either (i)
the date the Employee has actual knowledge of the claim, or (ii) ten days after the Internal
Revenue Service issues to the Employee either a written report proposing imposition of the
Excise Tax or a statutory notice of deficiency with respect to the Excise Tax, and shall apprise
the Company of the nature of the claim and the date on which the claim is requested to be paid.
The Employee shall not pay the claim prior to the expiration of a thirty (30) day period
following the date on which Employee gives such notice to the Company (or such shorter period
ending on the date that any payment of taxes with respect to the claim is due). If the Company
notifies the Employee prior to the expiration of the above period that it desires to contest the
claim, the Employee shall: (A) give the Company any information reasonably requested by the
Company relating to the claim, (B) take such action in connection with contesting the claim as
the Company shall reasonably request in writing from time to time, including accepting legal
representation with respect to the claim by an attorney reasonably selected by the Company, (C)
cooperate with the Company in good faith in order to effectively contest the claim, (D) permit
the Company to participate in any proceedings relating to the claim; provided, however, that the
Company shall bear and pay directly all costs and expenses (including additional interest and
penalties) incurred in connection with such contest and shall indemnify, defend and hold the
Employee harmless, on an after-tax basis, for any Excise Tax or income tax, including interest
and penalties with respect thereto, imposed as a result of such representation and payment of
costs and expenses. Without limitation of the foregoing provisions of this Section 7(c), the
Company shall control all proceedings taken in connection with such contest and, at its sole
option, may pursue or forego any and all administrative appeals, proceedings, hearings and
conferences with the taxing authority in respect of the claim and may, at its sole option,
either direct the Employee to request or accede to a request for an extension of the statute of
limitations with respect only to the tax claimed, or pay the tax claimed and sue for a refund or
contest the claim in any permissible manner, and the Employee agrees to prosecute such contest
to a determination before any administrative tribunal, in a court of initial jurisdiction and in
one or more appellate courts, as the Company shall determine; provided, however, that if the
Company directs the Employee to pay the claim and sue for a refund, the Company shall advance
the amount of the required payment to the Executive, on an interest-free basis and shall
indemnify and hold the Employee harmless, on an after-tax basis, from any Excise Tax or income
tax, including interest or penalties with respect thereto, imposed with respect to any advance
or with respect to any imputed income in relation to any advance; and further provided that any
extension of the statute of limitations requested or acceded to by the Employee at the Company’s
request and relating to payment of taxes for the taxable year of the Employee with respect to
which the contested amount is claimed to be due is limited solely to the contested amount.
Furthermore, the Company’s control of the contest shall be limited to issues with respect to
which a Gross-Up Payment would be payable under the Agreement and the Employee shall be entitled
to settle or contest, as the case may be, any other issue raised by the Internal Revenue Service
or any other taxing authority.

(d) If, after the receipt by the Employee of an amount advanced by the Company pursuant to
Section 7(c), the Employee becomes entitled to receive any refund with respect to the claim, the
Employee shall (subject to the Company’s complying with the requirements of Section 7(c))
promptly pay to the Company the amount of that refund (together with any interest paid or
credited thereon after taxes applicable thereto). If, after the receipt by the Employee of an
amount advanced by the Company pursuant to Section 7(c), a determination is made that the
Employee shall not be entitled to any refund with respect to the claim and the Company does not
notify the Employee of its intent to contest such denial of refund prior to the expiration of
thirty (30) days after the determination, then the advance shall be forgiven and shall not be
required to be repaid and the amount of the advance shall offset, to the extent thereof, against
the amount of Gross-Up Payment required to be paid.

Definition of “Change in Control”: For purposes of this Section 7, a “Change in Control” means,
and shall be deemed to have taken place, if (1) any person or entity or group of affiliated
persons or entities, including a group which is deemed a “person” by Section 13(d)(3) of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), after the date hereof is or
becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or
indirectly, of securities of the Company representing 40% or more of the combined voting power
of the Company’s then outstanding securities; (2) during any period of two consecutive years,
individuals who at the beginning of such period constitute the Board cease for any reason to
constitute at least a majority thereof, unless the election, or the nomination for election by
the Company’s stockholders, of each new Board member was approved by a vote of at least
three-fourths (3/4) of the Board members then still in office who were Board members at the
beginning of such period; (3) any reorganization, consolidation, merger or similar transaction
involving the Company in which the Company is not the continuing or surviving corporation or
pursuant to which the Company’s securities would be converted into cash, securities or other
property (other than a merger of the Company in which the holders of the Company’s voting
securities immediately prior to the merger have more than 50% of the combined voting power of
the securities of the corporation or other entity resulting from or surviving such merger,
calculated on a fully-diluted basis in accordance with generally accepted accounting principles
after giving effect to such merger, immediately after such merger); or (4) any sale, lease,
exchange or other transfer (in one transaction or a series of related transactions) of all, or
substantially all, of the assets of the Company.

Definition of “In Anticipation Of”: For purposes of this Section 7, the involuntary termination
by the Company of the Employee’s employment (including by way of the Company giving written
notice to the Employee pursuant to Section 1 that the Company intends to permit the Agreement to
expire without automatic extension after the next succeeding Expiration Date) shall be deemed to
have been “In Anticipation Of” a Change in Control if such termination (A) was at the request of
an unrelated third party who has taken steps reasonably calculated to effect a Change in
Control, or (B) otherwise arose in connection with a Change in Control.

	8.	 	CONFIDENTIAL INFORMATION. Employee acknowledges that the nature of Employee’s engagement by
the Company is such that Employee shall have access to information of a confidential and/or
trade secret nature which has great value to the Company and which constitutes a substantial
basis and foundation upon which the business of the Company is based. Such information
includes financial, manufacturing and marketing data, techniques, processes, formulas,
developmental or experimental work, work in process, methods, trade secrets (including,
without limitation, customer lists and lists of customer sources), or any other secret or
confidential information relating to the products, services, customers, sales or business
affairs of the Company (the “Confidential Information”). Employee shall keep all such
Confidential Information in confidence during the term of this Agreement and at any time
thereafter and shall not disclose any of such Confidential Information to any other person,
except to the extent such disclosure is (i) necessary to the performance of this Agreement and
in furtherance of the Company’s best interests, (ii) required by applicable law, (iii)
lawfully obtainable from other sources, or (iv) authorized by the Company. Upon termination
of Employee’s employment with the Company, Employee shall deliver to the Company, or certify
to the Company of the destruction of, all documents, records, notebooks, work papers, and all
similar material containing any of the foregoing information, whether prepared by Employee,
the Company or anyone else.

	9.	 	NON-COMPETITION. In order to protect the Confidential Information, Employee agrees that
during the term of Employee’s employment, and for a period of one (1) year thereafter,
Employee shall not, directly or indirectly, whether as an owner, partner, shareholder, agent,
employee, creditor, or otherwise, promote, participate or engage in any activity or other
business competitive with the Company’s business in any jurisdiction in which the Company
operates at the time of such termination if such activity or other business involves any use
by the Employee of any of the Confidential Information.

	10.	 	NONINTERFERENCE WITH EMPLOYEES. In order to protect the Confidential Information, Employee
agrees that during the term hereof and for a period of one (1) year thereafter, Employee will
not, directly or indirectly, solicit any employee of the Company to leave such employment.

	11.	 	INDEMNITY. In addition to any other separate agreement with the Company concerning
indemnification, to the fullest extent permitted by applicable law and the bylaws of the
Company, as from time to time in effect, the Company shall indemnify Employee and hold
Employee harmless for any acts or decisions made in good faith while performing services for
the Company, and the Company shall use its best efforts to obtain coverage for Employee
(provided the same may be obtained at reasonable cost) under any liability insurance policy or
policies now in force or hereafter obtained during the term of this Agreement that cover other
officers of the Company having comparable or lesser status and responsibility. To the same
extent, the Company will pay and, subject to any legal limitations, advance all expenses,
including reasonable attorneys’ fees and costs of court approved settlements, actually and
necessarily incurred by Employee in connection with the defense of any action, suit or
proceeding and in connection with any appeal thereon, which has been brought against Employee
by reason of Employee’s service as an officer or agent of the Company.

	12.	 	REMEDIES. The parties hereto agree that the services to be rendered by Employee pursuant to
this Agreement, and the rights and privileges granted to the Company pursuant to this
Agreement, are of a special, unique, extraordinary and intellectual character, which gives
them a peculiar value, the loss of which cannot be reasonably or adequately compensated in
damages in any action at law, and that a breach by Employee of any of the terms of this
Agreement will cause the Company great and irreparable injury and damage. Employee hereby
expressly agrees that the Company shall be entitled to the remedies of injunction, specific
performance and other equitable relief to prevent a breach of this Agreement by Employee. This
Section 12 shall not be construed as a waiver of any other rights or remedies which the
Company may have for damages or otherwise.

	13.	 	SEVERABILITY. If any provision of this Agreement is held to be unenforceable for any reason,
it shall be adjusted rather than voided, if possible, to achieve the intent of the parties to
the extent possible. In any event, all other provisions of this Agreement shall be deemed
valid and enforceable to the extent possible.

	14.	 	SUCCESSORS AND ASSIGNS. This Agreement shall inure to the benefit of and be binding upon the
Company and its successors and assigns and any such successor or assignee shall be deemed
substituted for the Company under the terms of this Agreement for all purposes. As used
herein, “successor” and “assignee” shall include any person, firm, corporation or other
business entity which at any time, whether by purchase, merger or otherwise, directly or
indirectly acquires the stock of the Company or to which the Company assigns this Agreement by
operation of law or otherwise. The obligations and duties of Employee hereunder are personal
and otherwise not assignable. Employee’s obligations and representations under this Agreement
will survive the termination of Employee’s employment, regardless of the manner of such
termination.

	15.	 	NOTICES. Any notice or other communication provided for in this Agreement shall be in
writing and sent if to the Company to its principal executive office at:

Corinthian Colleges, Inc.

6 Hutton Centre Drive, Suite 400

Santa Ana, California 92627

Phone: (714) 427-3000; Facsimile: (714) 427-3013

Attention: General Counsel

or at such other address as the Company may from time to time in writing designate, and if to
Employee at such address as Employee may from time to time in writing designate (or, if not so
designated, at the last address for such Employee on the employment records of the Company).
Each such notice or other communication shall be effective (i) if given by telecommunication,
when transmitted to the applicable number so specified in (or pursuant to) this Section 15 and a
verification of receipt is received, (ii) if given by mail, three days after such communication
is deposited in the mails with first class postage prepaid, addressed as aforesaid or (iii) if
given by any other means, when actually delivered at such address.

	16.	 	ENTIRE AGREEMENT. This Agreement contains the entire agreement of the parties relating to
the subject matter hereof and supersedes any prior agreements, undertakings, commitments and
practices relating to Employee’s employment by the Company.

	17.	 	AMENDMENTS. No amendment or modification of the terms of this Agreement shall be valid
unless made in writing and duly executed by both parties.

	18.	 	WAIVER. No failure on the part of any party to exercise or delay in exercising any right
hereunder shall be deemed a waiver thereof or of any other right, nor shall any single or
partial exercise preclude any further or other exercise of such right or any other right.

	19.	 	GOVERNING LAW. This Agreement, and the legal relations between the parties, shall be
governed by and construed in accordance with the laws of the State of California without
regard to conflicts of law doctrines and any court action arising out of this Agreement shall
be brought in any court of competent jurisdiction within the State of California, County of
Orange.

	20.	 	ARBITRATION. As a material inducement to enter into this Agreement, Employee and the Company
each hereby agree that any “Claims” or “Controversies” (as defined below) arising out of or in
respect to this Agreement (or its validity, interpretation or enforcement), or Employee’s
employment or termination, that Employee may have against the Company or it officers,
directors, employees, or agents, in their capacity as such, or that the Company may have
against Employee, shall be resolved solely through binding arbitration. EMPLOYEE AND THE
COMPANY EACH HEREBY ACKNOWLEDGE THAT THIS AGREEMENT TO ARBITRATE MEANS THAT EMPLOYEE AND THE
COMPANY ARE RELINQUISHING HIS/HER/ITS RIGHTS TO EITHER A JURY TRIAL OR COURT TRIAL FOR THE
RESOLUTION OF ANY CLAIMS THAT EMPLOYEE AND THE COMPANY MAY HAVE AGAINST THE OTHER.

The Terms “Claims” or “Controversies” arising out of this Agreement or Employee’s employment or
termination means and includes all claims for breach of this Agreement, harassment and/or
discrimination (including sexual harassment and harassment or discrimination based on race,
color, religion, age, sex, sexual orientation, ancestry, national origin, marital status,
military service, pregnancy, physical or mental disability, medical condition or any other
protected class or condition), breach of any contract or covenant (express or implied), tort
claims, wrongful termination, whistle-blowing and all other claims relating to this Agreement or
Employee’s employment or termination, except that claims covered by the Workers’ Compensation
Act and claims for unemployment benefits are not covered by this agreement to arbitrate. All
Claims or Controversies shall be submitted to a single neutral arbitrator. The arbitration shall
take place in Orange County, California, unless otherwise mutually agreed. The arbitrator shall
be mutually agreed-upon by Employee and the Company. If Employee and the Company cannot agree
upon an arbitrator, the selection process shall be governed by the employment arbitration rules
and procedures of the American Arbitration Association (“AAA”). Regardless of the arbitrator
chosen, the arbitration proceedings shall be governed by the then current AAA procedural rules,
except that if a contrary rule exists: (1) all monetary or provisional remedies available under
applicable state or federal statutory law or common law will remain available to both parties,
(2) except as mutually agreed upon by the parties, there will be no limitation on discovery
beyond that which exists in cases litigated in Orange County Superior Court and (3) the
California Rules of Evidence shall apply to the arbitration hearing.

In connection with any arbitration proceeding commenced hereby, the prevailing party shall be
entitled to reimbursement of its reasonable attorney’s fees and costs, including arbitrator
fees. This agreement to arbitrate and arbitration procedure is intended to be the exclusive
method of resolving all Claims or Controversies as described above between

Employee and the Company and judgment upon the award rendered by the arbitrator hereunder may be
entered in any court having jurisdiction thereof.

	21.	 	WITHHOLDING. All compensation payable hereunder, including salary and other benefits, shall
be subject to applicable taxes, withholding and other required, normal or elected employee
deductions.

	22.	 	COUNTERPARTS. This Agreement and any amendment hereto may be executed in one or more
counterparts. All of such counterparts shall constitute one and the same agreement and shall
become effective when a copy signed by each party has been delivered to the other party.

	23.	 	HEADINGS. Section and other headings contained in this Agreement are for convenience of
reference only and shall not affect in any way the meaning or interpretation of this
Agreement.

1

	 	 	24.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

CORINTHIAN COLLEGES, INC.

By:

Name:

Its:

EMPLOYEE

     

David G. Moore

2exv4w18

 

Exhibit 4.18

Dialysis Organization Agreement

     
This Dialysis Organization Agreement (this
“Agreement”) is made by and between Amgen USA Inc.
(“Amgen”) and National Medical Care, Inc.
(“NMC”) to set forth the terms and conditions upon
which NMC shall purchase Products and Amgen shall pay rebates.

     
Amgen and NMC hereby agree as follows:

		
	1.	
    DEFINITIONS

		
	 	
     When used with initial capitals herein, the following terms
    shall have the meanings ascribed to them below:

		
	1.1.	
    “Affiliate” of a given entity shall mean an entity
    that controls, is controlled by, or under common control with
    such given entity. Control shall mean ownership of more than
    fifty percent (50%) of the voting stock of an entity or, for
    non-stock entities, the right to more than fifty percent (50%)
    of the profits of such entity.
	 
	1.2.	
    “Authorized Wholesalers” shall mean those wholesalers
    listed on Schedule 1.2, as such list may be modified
    pursuant to Section 2.3.
	 
	1.3.	
    “Data” shall mean the data provided by NMC to Amgen
    hereunder in accordance with Article 4.
	 
	1.4.	
    “Designated Affiliates” shall mean any Affiliate of
    NMC listed on Schedule 1.4, as such list may be
    modified pursuant to Section 2.2.
	 
	1.5.	
    [*]
	 
	1.6.	
    “HIPAA” shall mean the Health Insurance Portability
    and Accountability Act of 1996 and its implementing regulations,
    each as amended.
	 
	1.7.	
    “Individually Identifiable Health Information” shall
    have the meaning specified in HIPAA.
	 
	1.8.	
    “Information Sheet” shall mean the information sheet
    attached hereto.
	 
	1.9.	
    “Managed Centers” shall mean an entity for which NMC
    provides management and administrative services including the
    purchase and billing of Products, and that is listed on
    Schedule 1.9, as such list may be modified pursuant
    to Section 2.2.
	 
	1.10.	
    “Products” shall mean the Amgen products specified on
    the Information Sheet.
	 
	1.11.	
    [*]
	 
	1.12.	
    [*]
	 
	1.13.	
    “WAC” shall mean the wholesaler acquisition cost
    established by Amgen in its sole discretion from time to time.
    WAC is subject to change by Amgen in its sole discretion at any
    time, by any amount, without notice, provided, however, that
    Amgen shall use commercially reasonable efforts to notify NMC of
    any change to WAC.

		
	2.	
    PURCHASE AND SALE OF PRODUCTS

		
	2.1.	
    Discounts. [*]
	 
	2.2.	
    Affiliates. Only purchases of Products made by NMC, its
    Designated Affiliates and Managed Centers shall be eligible for
    the pricing, discounts and rebates granted pursuant to this
    Agreement. NMC shall have the right to add or remove its
    Affiliates to or from the list of Designated Affiliates and add
    or remove Managed Centers to or from the list thereof by thirty
    (30) days prior written notice to Amgen upon Amgen’s
    approval, which shall not be unreasonably withheld or delayed.
    In the event of a change to

1

 

		
		
    information regarding a Designated Affiliate or Managed Center
    (such as address), NMC shall promptly notify Amgen and Amgen
    shall update the relevant list. Amgen shall for cause have the
    right to add or remove Affiliates of NMC from the list of
    Designated Affiliates and Managed Centers from the list thereof
    by thirty (30) days prior written notice to NMC. NMC shall
    ensure compliance with the terms and conditions of this
    Agreement applying to NMC by its Designated Affiliates and
    Managed Centers. NMC shall be jointly and severally liable for
    the acts and omissions of its Affiliates and Managed Centers,
    and Amgen shall have the right (but not the obligation) to
    proceed directly against NMC in the event of a breach of this
    Agreement by any such Affiliate or Managed Center, without first
    proceeding against such Affiliate or Managed Center.
	 
	2.3.	
    Authorized Wholesalers. Only Products purchased from
    Authorized Wholesalers shall be eligible for the [*]
    granted pursuant to this Agreement. NMC shall have the right to
    remove wholesalers from the list of Authorized Wholesalers by
    thirty (30) days prior written notice to Amgen, and shall
    have the right to add wholesalers to the list of Authorized
    Wholesalers by thirty (30) days notice to Amgen upon
    Amgen’s approval, which shall not be unreasonably withheld
    or delayed. Amgen shall have the right to add or remove
    wholesalers from the list of Authorized Wholesalers by thirty
    (30) days prior written notice to NMC. In the event of any
    such removal by Amgen, Amgen shall work with NMC to transition
    NMC’s purchasing to an Authorized Wholesaler and shall use
    reasonable efforts to establish a direct purchasing relationship
    in any interim period between the removal of the removed
    Authorized Wholesaler and the initiation of purchases from a new
    Authorized Wholesaler, if no alternative Authorized Wholesaler
    exists at such time. Any such relationship shall be subject to
    credit qualification and the approval by Amgen of an application
    for direct ship account.
	 
	2.4.	
    Own Use. Only Products purchased for NMC’s, its
    Designated Affiliates’ or its Managed Centers’
    “own use” for the treatment of dialysis patients shall
    be eligible for the [*] granted pursuant to this
    Agreement. NMC, its Designated Affiliates and its Managed
    Centers covenant that they shall not seek any such [*]
    for any Products not for its or their “own use” for
    the treatment of dialysis patients, and shall promptly notify
    Amgen in the event Amgen does provide NMC, its Designated
    Affiliate or a Managed Center any such [*].
	 
	2.5.	
    [*]
	 
	2.6.	
    Vial Sizes. NMC agrees that it and its Affiliates and
    Managed Centers shall notify Amgen if it desires to modify in
    its relative mix of Product types in their purchases from its
    historical mix. NMC shall give Amgen at least six months’
    prior written notice should NMC intend to modify the percentage
    of its purchases made up by any particular SKU deviate by more
    than 15% from the previous calendar quarter unless Amgen’s
    prior written consent shall have been obtained, which will not
    be unreasonably withheld. By way of example, if
    EPOGEN®
    2,000 unit/mL (NDC 55513-126-01) made up 35% of the aggregate
    purchases of Amgen Products by NMC, its Affiliates and Managed
    Centers in the first calendar quarter of given year, it shall
    make up no less than 29.75% (i.e. 85% of 35%) and no more than
    40.25% (i.e. 115% of 35%) of the aggregate purchases of Amgen
    Products by NMC, its Affiliates and Managed Centers in the
    second calendar quarter of such year, unless NMC shall have
    given Amgen six months’ prior written notice of such
    change. NMC shall promptly notify and consult with Amgen should
    it consider a material modification to its Product type mix. The
    purpose of this section is to allow Amgen adequate time to
    adjust its manufacturing processes. Amgen will use commercially
    reasonable efforts to modify its processes to meet the new mix,
    and will commence shipping the new mix when available.

		
	3.	
    REBATES

		
	3.1.	
    Earning and Vesting of Rebates. [*]
	 
	3.2.	
    Payment of Rebates. [*]
	 
	3.3.	
    Verification and Audit. [*]
	 
	3.4.	
    Adjustments for Changes. [*]

2

 

		
	3.5.	
    Treatment of Discounts and Rebates. NMC agrees that it,
    its Affiliates and Managed Centers shall properly disclose and
    account for all discounts and rebates earned hereunder, in
    whatever form, in compliance with all applicable federal, state,
    and local laws and regulations, including §1128B(b) of the
    Social Security Act and its implementing regulations. NMC also
    agrees that it, its Affiliates and Managed Centers shall
    (i) claim the benefit of such discount or rebate received
    in the fiscal year in which such discount or rebate was earned
    or the year after, (ii) fully and accurately report the
    value of such discount or rebate in any cost reports filed under
    Title XVIII or Title XIX of the Social Security Act,
    or a state health care program, and (iii) provide, upon
    request by the U.S. Department of Health and Human Services
    or a state agency or any other federally funded state health
    care program, the information furnished to NMC, its Affiliates
    or Managed Centers by Amgen concerning the amount or value of
    such discount or rebate. Amgen shall properly disclose and
    account for all discounts and rebates given hereunder in
    accordance with its obligations under all applicable federal,
    state, and local laws and regulations, including §1128B(b)
    of the Social Security Act and its implementing regulations.
	 
	3.6.	
    Reports. Amgen shall provide to NMC a quarterly statement
    of the rebates earned hereunder with the itemization of Product
    purchases made in a particular calendar quarter, broken down by
    Designated Affiliates and Managed Centers; and any other
    information that NMC may reasonably request that is reasonably
    available to Amgen and necessary for NMC to obtain in order to
    comply with its obligations hereunder or to calculate or confirm
    purchases, discounts, or rebates due or paid. NMC agrees that it
    will provide such information to its Affiliates and Managed
    Centers in a timely manner in order to allow such Affiliates and
    Managed Centers to meet their reporting and other obligations
    hereunder and under applicable law and regulation.

		
	4.	
    PRODUCT DATA

		
	4.1.	
    Data Submission. NMC shall provide the data specified in
    Exhibit 3.1 to Amgen (or to a data collection vendor
    specified by Amgen) within thirty (30) days of the end of
    each calendar month. Such Data shall be provided in the format
    set forth in such Schedules.
	 
	4.2.	
    HIPAA Compliance. NMC shall not provide Amgen (or any
    specified data collection vendor) any Data in violation of
    HIPAA. Any Individually Identifiable Health Information shall
    have been de-identified in accordance with HIPAA prior to
    provision to Amgen or its designee. Notwithstanding anything
    contained herein to the contrary, in order to assure compliance,
    as determined by either party in its reasonable discretion, with
    any existing federal, state or local statute, regulation or
    ordinance relating to patient privacy of medical records, or at
    any time following the enactment of any federal, state, or local
    law or regulation relating to patient privacy of medical records
    that in any manner reforms, modifies, alters, restricts, or
    otherwise affects any of the data received or to be received in
    connection with any of the incentives contemplated under this
    Agreement, either party may upon thirty (30) days’
    notice, seek to modify this Agreement with respect to the
    affected incentive. NMC and Amgen shall meet and in good faith
    seek to mutually agree to modify this Agreement to accommodate
    any such change in law or regulation, with the intent to, if
    possible, retain the essential terms of the affected incentive
    and pricing structure. If the parties, after a reasonable time,
    are unable to agree upon such a modification, Amgen shall be
    entitled to terminate the affected incentive upon thirty
    (30) days’ notice or upon the date such change in law
    or regulation goes into effect, whichever is earlier.
    Notwithstanding the foregoing, in the event Amgen terminates
    such affected incentive as contemplated in the preceding
    sentence, any amount earned by NMC under such incentive through
    the effective date of such change in law or regulation or the
    date of termination, as applicable, shall be due and owing to
    NMC. In such a case, NMC agrees that it shall provide Amgen with
    such data as may be necessary for Amgen to calculate such
    incentive. In the event NMC fails to provide Amgen with such
    data, Amgen shall have no obligation to pay such incentive.
	 
	4.3.	
    Case Identifier. NMC shall consistently use a unique
    alpha-numeric code (which shall not be derived from Individually
    Identifiable Health Information) as a “case
    identifier” to track the care rendered to each individual
    patient over time, and such case identifier shall be included in
    the data provided to Amgen. The key or list matching patient
    identities to their unique case identifiers shall not be
    provided to Amgen.

3

 

		
	4.4.	
    Data Use. Amgen shall have the right to use Data to
    support verification of the services referenced in this
    Agreement, for Amgen-sponsored research and analysis,
    development of marketing materials, running internal trending
    analyses, overall analyses of how to improve treatment of
    patients on dialysis, creating tools by Amgen marketing
    personnel, and other internal Amgen business purposes.
    Notwithstanding the foregoing, without NMC’s prior written
    consent (such consent not to be unreasonably withheld or
    delayed): (i) Amgen shall not disclose to third parties the
    health information data provided by NMC hereunder except
    pursuant to public health activities and to agents of Amgen
    bound by commercially reasonable obligations of confidentiality
    (or as required by law or regulation); and (ii) Amgen shall
    not sell or resell any such data or derivative works thereof to
    any third party.

		
	5.	
    WARRANTIES, REPRESENTATIONS AND COVENANTS

		
	5.1.	
    Power and Authority. Each party represents and warrants
    to the other that this Agreement: (a) has been duly
    authorized, executed, and delivered by it, (b) constitutes
    a valid, legal, and binding agreement enforceable against it in
    accordance with the terms contained herein, and (c) does
    not conflict with or violate any of its other contractual
    obligations, expressed or implied, to which it is a party or by
    which it may be bound. The party executing this Agreement on
    behalf of NMC specifically warrants and represents to Amgen that
    he or she is authorized to execute this Agreement on behalf of
    and has the power to bind NMC, its Affiliates and Managed
    Centers to the terms set forth in this Agreement. The party
    executing this Agreement on behalf of Amgen specifically
    warrants and represents to NMC that he or she is authorized to
    execute this Agreement on behalf of and has the power to bind
    Amgen.
	 
	5.2.	
    Compliance with Law and Regulation. Amgen shall, and NMC,
    its Affiliates and Managed Centers shall, comply with all
    applicable law and regulation.
	 
	5.3.	
    Products. Amgen warrants that, as of the time of delivery
    by Amgen to a common carrier or other third party that:

			
	 	5.3.1.	
    the Products are manufactured and labeled in accordance with all
    applicable federal, state and local laws and regulations
    pertaining to the manufacturing of the Products including
    without limitation, the Federal Food, Drug and Cosmetic Act and
    implementing regulations and meet all the specifications for
    effectiveness and reliability as required by the United States
    Food and Drug Administration; and;
	 
	 	5.3.2.	
    when used in accordance with the directions on their labeling,
    the Products are fit for the purposes and indications described
    in such labeling.

		
	 	
    Amgen agrees that it will promptly notify NMC if it determines
    that there has been any material defect in any of the Products
    delivered to NMC.

		
	5.4.	
    NO OTHER WARRANTIES. OTHER THAN THE WARRANTIES EXPRESSLY
    SET FORTH HEREIN, NEITHER PARTY MAKES, AND EACH PARTY EXPRESSLY
    DISCLAIMS, ALL OTHER WARRANTIES, INCLUDING THOSE OF
    NONINFRINGEMENT, MERCHANTABILITY AND FITNESS FOR A PARTICULAR
    PURPOSE.

		
	6.	
    INDEMNITY AND INSURANCE

		
	6.1.	
    Insurance. Each of the parties agrees that it shall
    secure and maintain in full force and effect throughout the term
    of this Agreement (and following termination, to the extent
    necessary to cover any claims arising from the Agreement)
    comprehensive general liability insurance. Such insurance shall
    provide, among other things, product liability, professional
    liability, workmen’s compensation, and broad form
    contractual liability coverage for its indemnification
    obligations hereunder, and shall have limits acceptable to the
    other party. Any limits on each of a party’s insurance
    coverage shall not be construed to create a limit on such
    party’s liability with respect to its obligations under
    this Agreement. The parties shall have the right to satisfy its
    obligations under this Section 6.1 through self-insurance.

4

 

		
	6.2.	
    Indemnity.

			
	 	6.2.1.	
    By Amgen. Amgen agrees to indemnify, defend and hold
    harmless NMC, its Affiliates and Managed Centers, and its and
    their respective employees, officers and directors from and
    against any and all amounts payable to third parties pursuant to
    a written settlement agreement or court order (including but not
    limited to reasonable attorney fees incurred by NMC in the
    defense of a third party claim prior to Amgen’s assumption
    of the defense thereof) (“Third Party Awards”) that
    result directly from: (a) Products that as of the date of
    shipment by Amgen: (i) contain defects in material and
    workmanship, (ii) are adulterated or misbranded within the
    meaning of applicable provisions of the FDC Act, or
    (iii) are prohibited from being introduced into interstate
    commerce by Section 301 of the FDC Act or Section 351
    of the Public Health Service Act, or (b) Amgen’s gross
    negligence or willful misconduct; provided that such indemnity
    shall not apply to Third Party Awards arising out of the
    negligent or willful actions or omissions of NMC, its Affiliates
    or Managed Centers, or its or their respective agents,
    employees, representatives, successors or assigns, or to the
    extent arising out of a matter for which NMC is required to
    indemnify Amgen pursuant to Section 6.2.2 of this
    Agreement, or due to defects in the Products caused by persons
    other than Amgen or that result from neglect, misuse,
    unauthorized adulteration or modification, improper testing,
    handling or storage or any cause beyond the range of normal
    usage; and further provided that (a) Amgen is promptly
    notified in writing of any such third party claim for which this
    indemnity obligation may apply, (b) Amgen shall have sole
    control of the defense and settlement thereof, and (c) NMC
    cooperates fully and gives Amgen all requested information and
    assistance for such defense. The preceding paragraph sets forth
    NMC’s and its Affiliates’ sole remedy for claims of
    Product defect, adulteration or misbranding.
	 
	 	6.2.2.	
    By NMC. NMC, its Affiliates and Managed Centers agree to
    indemnify, defend and hold harmless Amgen and its respective
    employees, officers and directors from and against any and all
    Third Party Awards that result from NMC’s, its
    Affiliates’ or its Managed Centers’ transportation,
    handling, storage, promotion or sale of the Products and not
    arising solely out of Amgen’s negligence, or a matter for
    which Amgen is required to indemnify NMC pursuant to the above
    paragraph, provided that (a) NMC is promptly notified in
    writing of any such third party claim for which this indemnity
    obligation may apply, (b) NMC shall have sole control of
    the defense and settlement thereof, and (c) Amgen
    cooperates fully and gives NMC all requested information and
    assistance for such defense.

		
	7.	
    TERM AND TERMINATION

		
	7.1.	
    Term. This Agreement shall come into effect as of the
    Term Start Date and shall expire as of the Term End Date, unless
    sooner terminated in accordance with this Article 7.
	 
	7.2.	
    Termination. Either party may terminate this Agreement in
    the event of an uncured material breach following thirty
    (30) days written notice of same (which termination shall
    be automatically effective at the end of such thirty
    (30) day period should such breach remain uncured). In
    addition, Amgen shall have the right to terminate this Agreement
    without cause by thirty (30) days written notice to NMC.
	 
	7.3.	
    Compliance with or Change in Law or Regulation.
    Notwithstanding anything contained herein to the contrary, in
    order to assure compliance with any existing federal, state or
    local statute, regulation or ordinance, or at any time following
    the enactment of any federal, state, or local law, regulation,
    policy, program memorandum or other interpretation, modification
    or utilization guideline by any payer that in any manner
    reforms, modifies, alters, restricts, or otherwise affects the
    pricing of or reimbursement available for any of the Products or
    restricts NMC’s ability to provide, or Amgen’s ability
    to receive or use Data in accordance with this Agreement,
    including but not limited to the enactment of any reimbursement
    rule, guideline, final program memorandum, coverage decision,
    pricing decision, instruction or the like by the Centers for
    Medicare and Medicaid Services (“CMS”) or one of its
    contractors (carriers or fiscal intermediaries), or any change
    in reimbursement systems that in any manner reforms, modifies,
    alters, restricts or otherwise affects the reimbursement
    available to NMC for any of the

5

 

		
		
    Products, upon ten (10) days prior written notice,
    (i) either party may terminate this Agreement,
    (ii) Amgen may, in its sole discretion, modify any pricing,
    rebate or discount terms contained herein, or (iii) Amgen
    may, in its sole discretion, exclude any Designated Affiliates
    or Managed Centers from participating in this Agreement. Without
    limiting the foregoing, any change, modification or further
    clarification to the Medicare Prescription Drug Improvement and
    Modernization Act of 2003 (“MMA”) or any rules or
    regulations promulgated thereunder, or the Erythropoeitin
    Monitoring Policy for ESRD Patients that occurs subsequent to
    the Term Start Date would specifically trigger the right to the
    termination or modification referenced herein. Additionally, to
    assure compliance with any existing federal, state or local
    statute, regulation or ordinance, Amgen reserves the right, in
    its sole discretion, to exclude any Affiliates or Managed
    Centers from the pricing, rebate and discount provisions of this
    Agreement and/or to reasonably modify any pricing, rebate or
    discount terms contained herein.
	 
	7.4.	
    [*]
	 
	7.5.	
    Effect of Termination. Upon any termination or expiration
    of this Agreement, any earned and vested rebates shall be paid
    in accordance with the terms set forth in Article 3.
    Upon termination of this Agreement for any reason other than
    actual or threatened breach by NMC, any earned but unvested
    rebates shall vest as of the effective date of such termination.
    In the event of any termination during a calendar quarter, Amgen
    shall pro-rate any data used in calculating payments hereunder,
    and such payments, as appropriate.
	 
	7.6.	
    Survival. The following provisions shall survive any
    expiration or termination of this Agreement:
    Sections 3.2-3.5 (with respect to periods prior to
    such expiration or termination) and 7.5 and
    Articles 4 (with respect to periods prior to such
    expiration or termination), 6 and 8.

		
	8.	
    MISCELLANEOUS

		
	8.1.	
    Amendment. Except as expressly set forth herein, no
    amendment of this Agreement shall be effective unless expressed
    in a writing signed by each of the parties. Amgen reserves the
    right to amend any discount, rebate or other incentive program
    described in this Agreement at any time as provided in
    Section 7.3 by giving NMC prior written notice
    thereof. In the event of such amendment, Amgen shall have the
    right, but not the obligation, to immediately vest any unvested
    rebates as of the effective date of any amendment. In addition,
    if determined by Amgen to be necessary or useful to accommodate
    such amendment, Amgen shall have the right to calculate any
    rebates as of the effective date of such amendment.
	 
	8.2.	
    Assignment. Neither party shall have the right to assign
    this Agreement without the other’s prior written consent,
    and any attempted assignment shall be void. Notwithstanding the
    foregoing, Amgen shall have the right to assign this Agreement,
    in its entirety, to an Affiliate. This Agreement shall be
    binding on the parties’ permitted successors and assigns.
	 
	8.3.	
    Conflicting Provisions. In the event of any conflict
    between this Agreement and any purchase order or invoice
    relating to the subject matter of this Agreement, including
    service fees, purchase orders or payment terms, this Agreement
    shall control.
	 
	8.4.	
    Construction. This Agreement shall be deemed to have been
    jointly drafted by the parties, and no rule of strict
    construction shall apply against either party. As used herein,
    the word “including” shall mean “including,
    without limitation.”
	 
	8.5.	
    Counterparts. This Agreement may be executed in one or
    more counterparts, each of which shall be considered an original.
	 
	8.6.	
    Currency. All amounts herein are set forth in United
    States Dollars.
	 
	8.7.	
    Force Majeure. Neither party will be liable for delays in
    performance or nonperformance of this Agreement or any covenant
    contained herein if such delay or nonperformance is a result of
    Acts of God, civil or military authority, civil disobedience,
    epidemics, war, failure of carriers to furnish transportation,

6

 

		
		
    strike or other labor disturbances, inability to obtain material
    or equipment, or any other cause of like nature beyond the
    control of such party.
	 
	8.8.	
    Further Assurances. The parties shall perform all further
    acts reasonably requested by the other party to effectuate the
    purposes of this Agreement.
	 
	8.9.	
    Governing Law. This Agreement shall be governed by the
    laws of the State of Delaware, excluding its choice of law
    rules. Each party hereby irrevocably submits to the jurisdiction
    of the state and Federal courts located in the State of
    Delaware, and agrees that any dispute arising out of or relating
    to this Agreement shall be heard in a state or Federal court
    located in Wilmington, Delaware, and agrees that it shall not
    assert any objection or defense of lack of jurisdiction,
    improper venue or forum non conveniens in any dispute brought in
    such courts. The parties agree that any such dispute shall be
    adjudicated as between the parties, and neither party shall seek
    certification as a class. Notwithstanding the foregoing, either
    party shall have the right to join any party ruled indispensable
    by the relevant court.
	 
	8.10.	
    Merger. This Agreement, together with the Information
    Sheet, constitutes the entire Agreement, written or oral, of the
    parties concerning the subject matter hereof. The Exhibits to
    this Agreement are hereby incorporated into and made a part of
    this Agreement. This Agreement supersedes any prior or
    contemporaneous agreements on the subject matter hereof,
    including any prior data use agreement between the parties.
	 
	8.11.	
    No Partnership. The relationship between Amgen and NMC,
    its Affiliates and Managed Centers is that of independent
    contractors, and not a partnership or an agency, franchise or
    other relationship. Neither party shall have the authority to
    bind the other.
	 
	8.12.	
    Notices. Any notice or other communication required or
    permitted hereunder shall be in writing and shall be deemed
    given or made five (5) days after deposit in the United
    States mail with proper postage for first-class registered or
    certified mail prepaid, return receipt requested, or when
    delivered personally or by facsimile (as shown by concurrent
    written transmission confirmation), or one (1) day
    following traceable delivery to a nationally recognized
    overnight delivery service with instructions for overnight
    delivery, in each case addressed to the address set forth for
    Amgen below, or for NMC, at the address set forth in the
    Information Sheet, or at such designated address that either
    party shall have furnished to the other in accordance with this
    Section 8.12:

	 	 	 	 	 
	 	 	
    If to Amgen:	 	 
	 	 	 	 	
    Amgen USA Inc.
	 	 	 	 	
    One Amgen Center Drive, M/S 37-2-B
	 	 	 	 	
    Thousand Oaks, CA 91320-1789
	 	 	 	 	
    Attn: Sr. Contract and Pricing Analyst — Nephrology
    Business Unit
	 	 	 	 	
    Fax: (805) 376-8558
	 	 	
    with a copy to:	 	 
	 	 	 	 	
    Amgen USA Inc.
	 	 	 	 	
    One Amgen Center Drive, M/S 28-2-D
	 	 	 	 	
    Thousand Oaks, CA 91320-1789
	 	 	 	 	
    Attn: General Counsel
	 	 	 	 	
    Fax: (805) 499-8011

		
	8.13.	
    Publicity. The terms and conditions of this Agreement and
    the amount and structures of any discount, rebate or other
    reduction in price described herein are the confidential
    information of the parties, and neither party shall disclose the
    same to any person or entity without the other’s prior
    written consent, except as necessary to comply with obligations
    pursuant to Section 3.5 or applicable law or
    regulation. NMC shall only share such information with those
    employees who have a need to know and shall only use such
    information for the purpose of fulfilling its obligations under
    this Agreement. Neither party shall make any press release in
    connection with the execution of this Agreement without the
    other party’s prior written consent.

7

 

		
	8.14.	
    Severability. Should any one or more of the provisions of
    this Agreement be determined to be illegal or unenforceable, the
    parties shall attempt, in good faith, to negotiate a
    modification of this Agreement so as to comply with the relevant
    law or regulation. Should they be unable to do so within thirty
    (30) days, either party shall have the right to terminate
    this Agreement upon ten (10) days prior written notice to
    the other.
	 
	8.15.	
    Waiver. No party shall be deemed to have waived any right
    hereunder, unless such waiver is expressed in a writing signed
    by such party.
	 
	8.16.	
    Direct Purchase of Products. NMC may purchase
    EPOGEN®
    S10, 10,000 U, 1 mL (10,000 U/mL) vial NDC
    55513-144-10;
    EPOGEN®
    M20, 20,000 U, 1 mL vials, NDC 55513-478-10 packaged
    as ten (10) vials per pack and four (4) packs per
    case; S4, 4,000 U, 1 mL vials, NDC 55513-148-10
    packaged as ten (10) vials per pack and ten (10) packs
    per case; and
    Aranesp®
    25 mcg, 1.0 mL vials, NDC 55513-010-04 packaged as
    four (4) vials per pack and ten (10) packs per case;
    40 mcg, 1.0 mL vials, NDC 55513-011-04 packaged as
    four (4) vials per pack and ten (10) packs per case;
    60 mcg, 1.0 mL vials, NDC 55513-012-04 packaged as
    four (4) vials per pack and ten (10) packs per case;
    100 mcg, 1.0 mL vials, NDC 55513-013-04 packaged as
    four (4) vials per pack and ten (10) packs per case;
    200 mcg, 1.0 mL vials, NDC 55513-014-01 packaged as
    one (1) vial per pack and four (4) packs per case;
    150 mcg, 0.75 mL single-use vials, NDC 55513-054-04
    packaged as four (4) vials per pack and ten (10) packs
    per case; 300 mcg, 1.0 mL single-use vials, NDC
    55513-015-01 packaged as one (1) vial per pack and four
    (4) packs per case;
    Aranesp®
    SingleJect®
    Prefilled Syringe 60 mcg, 0.3 mL (200 mcg/mL),
    single-use syringe, NDC 55513-039-04 packaged as 4 syringes
    per pack; 10 packs per case;
    Aranesp®
    SingleJect®
    Prefilled Syringe 100 mcg, 0.5 mL (200 mcg/mL),
    single-use syringe, NDC 55513-041-04 packaged as 4 syringes
    per pack; 10 packs per case;
    Aranesp®
    SingleJect®
    Prefilled Syringe 200 mcg, 0.4 mL (500 mcg/mL),
    single-use syringe, NDC 55513-044-01, packaged as 1 syringe
    per pack; 4 packs per case; and
    Aranesp®
    SingleJect®
    Prefilled Syringe 300 mcg, 0.6 mL (500 mcg/mL),
    single-use syringe, NDC 55513-046-01, packaged as 1 syringe
    per pack; 4 packs per case, NDC 55513-043-04 single-use
    syringe; four (4) syringes per pack; ten (10) packs
    per case, 150 mcg, 0.3 mL (500 mcg/mL) (the
    “Direct Product”) on a direct basis from Amgen in
    accordance with the terms set forth in Exhibit 8.16 which
    is incorporated herein by reference.

********

8

 

     
The parties have executed this Agreement by their designated
representatives set forth below.

	 	 	 	 	 	 	 
	
    AMGEN USA INC.	 	
    NATIONAL MEDICAL CARE, INC.
	 
	
    
    By:

    	 	
    /s/ Fred Manak
    	 	
    By:	 	
    /s/ Robert J. McGorty
    
	 	 	 	 	 	 	 
	 
	
    
    Name (print):

    	 	
    Fred Manak	 	
    Name (print):	 	
    Robert J. McGorty
	 	 	 	 	 	 	 
	 
	
    Title:	 	
    Director Contracts and Pricing	 	
    Title:	 	
    Vice President
	 	 	 	 	 	 	 
	 
	
    Date:	 	
    12/14/05	 	
    Date:	 	
    12/14/05
	 	 	 	 	 	 	 

9

 

Schedule 1.2

Authorized Wholesalers

     
[*]

10

 

Schedule 1.4

Designated Affiliates

(to be inserted)

11

 

Schedule 1.9

Managed Centers

(to be inserted)

12

 

Schedule 8.16

Approved Distribution Centers

Fresenius USA Manufacturing, Inc.

d/b/a Nephromed and affiliates

95 Hayden Avenue

Lexington, MA 92420-9192

13

 

Exhibit 3.1

Discount Terms and Conditions

		
	1	
    Rebate/Incentive Qualification Requirements. [*]

14

 

Exhibit 8.16

Terms for Purchase of Direct Product

     
Pursuant to Section 8.16 of the Agreement, the terms under
which NMC may purchase Direct Product on a direct basis from
Amgen are as follows:

		
	1.	
    Orders/Invoices. NMC shall place Direct Product orders
    with NMC Distribution Center. NMC Distribution Center shall
    transmit orders and receive corresponding invoices via
    electronic data interchange (“EDI”) in a format
    specified by Amgen.

		
	 	
     Orders may be submitted via facsimile, mail, or telephone to
    the address and telephone/fax numbers listed
    below. [*]
	 
	 	
     Amgen Customer Service may be reached at the following address
    and phone numbers:

	 	 	 	 	 
	 	 	
           Amgen USA Inc.	 	 
	 	 	
           Customer Service
    Department	 	
    Fax: 1-800-292-6436
	 	 	
           One Amgen Center Drive	 	
    Tel: 1-800-282-6436
	 	 	
           Thousand Oaks,
    CA 91320-1799	 	 

		
	2.	
    [*]
	 
	3.	
    Title and Risk of Loss. [*]
	 
	4.	
    Pricing for Direct Product. [*]
	 
	5.	
    Terms of Payment. NMC Distribution Center agrees to pay a
    [*] for Direct Product ordered, at terms of [*]
	 
	6.	
    Credit. NMC Distribution Center shall send annually,
    within one hundred twenty (120) days of Fresenius Medical
    Care Holdings, Inc.’s (“FMCH”) fiscal year end,
    or more frequently as requested by Amgen, copies of FMCH’s
    audited financial statements for such fiscal year to:

	 	 	 	 	 
	 	 	
    Amgen USA Inc.	 	 
	 	 	
    Customer Finance Department	 	 
	 	 	
    One Amgen Center Drive	 	 
	 	 	
    Thousand Oaks, CA 91320-1799	 	 

		
	 	
     If no audited financial statements are available, NMC
    Distribution Center shall send unaudited financial statements
    which are certified by NMC Distribution Center’s principal
    financial officer as being accurate in all material respects.
    Amgen shall not be obligated to ship Direct Product to NMC
    Distribution Center if there are any amounts past due on NMC
    Distribution Center’s account or if NMC Distribution
    Center’s outstanding balance due exceeds NMC Distribution
    Center’s predetermined credit limit. NMC Distribution
    Center shall supply Amgen written notice of the sale or transfer
    of all or substantially all of its assets of, or a controlling
    interest in, NMC Distribution Center at least thirty
    (30) days prior to such action if not otherwise prohibited
    by law or contractual obligations. Amgen reserves the right in
    its sole discretion to modify its credit policies and to require
    prepayment or satisfactory security at any time.

		
	7.	
    Sales Data. NMC Distribution Center shall submit all
    Direct Product sales data, including Customer returns,
    rebillings and associated credits to IMS America, Ltd.
    (“IMS”) and to any other third-party sales reporting
    organization as reasonably requested by Amgen, on a monthly
    basis, and within two (2) weeks after the close of each
    month. NMC Distribution Center shall provide all information and
    assistance reasonably required by Amgen to determine and verify
    Medicaid, other government, or third-party rebate claims or
    obligations. If NMC Distribution Center is unable to report such
    sales data to the agreed upon independent third-party sales
    reporting organization(s) due to unwillingness of the third
    party to deal with NMC Distribution Center, Amgen’s sole
    recourse shall be to terminate the Direct Product purchase
    components of this Agreement.
	 
	8.	
    Contracts and Chargebacks. NMC Distribution Center agrees
    to service contracts that Amgen has entered into with Customers
    in accordance with the terms specified in bid award
    notifications sent by Amgen to

15

 

		
		
    NMC Distribution Center. [*] Adjustments or credits will
    be made in accordance with Amgen’s Chargeback Policy
    (See Article One) attached hereto and incorporated
    herein. NMC Distribution Center further agrees to submit
    chargebacks to Amgen via EDI in a format acceptable to Amgen at
    least once per week, and in accordance with Amgen’s
    Chargeback Policy. NMC Distribution Center shall retain all
    documentation supporting such chargebacks for a period of
    eighteen (18) months from the date of sale and permit Amgen
    employees or contractors (who shall not be compensated by Amgen
    on a contingency basis) to review this documentation upon
    request.
	 
	9.	
    Product Returns. NMC Distribution Center shall comply
    with Amgen’s Product Return Policy (See
    Article Two) and all requirements of the Prescription Drug
    Marketing Act of 1987 (as amended from time to time).

			
	 	9.1	
    Returns by Customer to NMC Distribution Center: NMC Distribution
    Center shall notify Amgen of all Direct Product returned to NMC
    Distribution Center in the form of a negative chargeback. This
    will ensure that the proper adjustment is made to NMC
    Distribution Center’s account.
	 
	 	9.2	
    Returns by NMC Distribution Center to Amgen: Amgen shall
    only accept Direct Product returns from NMC Distribution
    Center that have been
    pre-authorized by Amgen
    Customer Service. Direct Product must be in original, unopened
    and undamaged cartons and returned within twelve
    (12) months post expiration and must be in full compliance
    with Amgen’s Product Return Policy (See
    Article Two) attached hereto and incorporated herein. Amgen
    will promptly issue credit to NMC Distribution Center in
    accordance with Amgen’s Product Return Policy.
	 
	 	9.3	
    Returns by Customer to Amgen: Amgen shall accept from Customer
    Direct Product returns that have been pre-authorized by Amgen
    Customer Service. NMC Distribution Center agrees to
    promptly issue credit to Customer returning Direct Product
    directly to Amgen and for which Amgen has issued a credit memo
    to NMC Distribution Center.

		
	10.	
    Rebillings and Associated Credits. NMC Distribution
    Center agrees to submit to Amgen all Customer rebillings and
    associated credits in conformance with Amgen’s Chargeback
    Policy.
	 
	11.	
    Product Recall. In the event of a recall, Amgen will
    promptly notify NMC Distribution Center and relevant
    Customer of such recall and arrange for Direct Product to be
    shipped directly to Amgen. Amgen will provide a third-party
    billing number (common carrier) to Customer and
    NMC Distribution Center for shipping of recalled Direct
    Product directly to Amgen. NMC Distribution Center shall
    provide a list of Customer names and addresses to Amgen who may
    have received recalled Direct Product. In consideration for
    NMC Distribution Center’s administrative expenses,
    Amgen will pay NMC Distribution Center for a list of each
    Customer that may have received recalled Direct Product in the
    amount equal to $1.00 per Customer name up to a maximum $100.00
    per distribution center. NMC Distribution Center shall
    render its services and assist Amgen in returning all recalled
    Direct Product to Amgen.

		
	 	
     Amgen shall provide reasonable compensation to
    NMC Distribution Center per HDMA standards for additional
    services that may be requested by Amgen. A credit memo will be
    issued to NMC Distribution Center for all recalled Direct
    Product returned to Amgen. NMC Distribution Center shall
    promptly issue credit to Customer for recalled Direct Product
    returned directly to Amgen for which Amgen has issued a credit
    memoranda to NMC Distribution Center. NMC Distribution
    Center may call Amgen Customer Service at
    1-800-282-6436 for
    further instructions in the event of a recall.

		
	12.	
    Applicable Laws and Regulations. Amgen and
    NMC Distribution Center agree to comply with all laws
    (local, state and federal) applicable to the purchase, handling,
    sale, and distribution of Direct Product. NMC agrees to provide
    Amgen with the statutory citation of all local and state laws
    and regulations contemplated by this Article 12. In
    the event there shall be a change in federal or state statutes
    (including, but not limited to Medicare or Medicaid statutes,
    Federal Food, Drug and Cosmetic Act (the “FDC Act”),
    and any other statutes governing distribution, handling,
    purchasing, or sale of drugs, medical supplies and durable
    medical equipment), case laws, regulations or general
    instructions, the interpretation of any of the foregoing, the
    adoption of new federal or state legislation, or a change in any
    third party reimbursement system, any of which are reasonably
    likely to materially and adversely affect the manner in which
    either party may perform

16

 

		
		
    or be compensated for its services under this Agreement or which
    shall make this Agreement unlawful, the parties shall
    immediately enter into good faith negotiations regarding a new
    service arrangement or basis for compensation for the services
    furnished pursuant to this Agreement that complies with the law,
    regulation, or policy. If good faith negotiations cannot resolve
    the matter within thirty (30) days, the parties shall
    terminate the Agreement.
	 
	13.	
    Diversion. NMC Distribution Center shall distribute
    Direct Product only to those approved Designated Affiliates and
    Managed Centers listed on Schedule 1.4 and
    Schedule 1.9. NMC Distribution Center shall
    promptly notify Amgen upon learning of any activity that appears
    to be diversion of Direct Product, including the sale,
    distribution or purchase of Direct Product for uses beyond the
    provision of care for dialysis patients, or the sale or
    distribution of Direct Product outside of the United States and
    Puerto Rico. Amgen may terminate this Agreement upon written
    notice if it is determined by Amgen, in its sole discretion,
    that NMC Distribution Center has purchased Direct Product from
    sources other than Amgen or distributed Direct Product to
    entities not listed on Schedule 1.4 and/or
    Schedule 1.9.

17

 

Article 1

Chargeback Policy

		
	1.	
    INITIAL SUBMISSIONS:

		
	 	
     Chargeback claims must be submitted via EDI in a format
    acceptable to Amgen. Claims must be received by Amgen no later
    than sixty (60) calendar days after NMC Distribution
    Center has invoiced the Customer. Each item must contain the
    information necessary to uniquely identify the Customer,
    including the Health Industry Number (HIN) and complete ship-to
    name and address, or other identifier as required by Amgen.

		
	2.	
    PROCESSING TIME:

		
	 	
     Amgen will process all initial chargeback claims received in an
    acceptable format within ten (10) business days. Once the
    chargeback claim has been processed, NMC Distribution
    Center will receive, by mail, the credit memoranda and/or
    discrepancy report.

		
	3.	
    DISCREPANCIES:

		
	 	
     Partial Rejections: If any item cannot be validated from the
    claim, it will be rejected and credit will not be issued for
    that item. NMC Distribution Center will receive the credit
    memoranda for the validated items in conjunction with the
    discrepancy report for rejected items. A reason will be given
    for each rejected item.
	 
	 	
     Full Rejections: Submissions not in an acceptable format or
    with a rejection rate greater than ten percent (10%) may be
    rejected in full. Upon such notification, NMC Distribution
    Center must correct the error(s) and electronically retransmit
    the entire claim.

		
	4.	
    RESUBMISSIONS:

		
	 	
     Amgen will accept resubmissions for rejected chargebacks within
    sixty (60) calendar days after NMC Distribution Center
    has been notified of the rejection. Claims must be submitted on
    Amgen’s discrepancy report with any corrections or
    additional information necessary to validate such claim.

		
	5.	
    CUSTOMER RETURNS:

		
	 	
     NMC Distribution Center must report its Customer returns
    as “negative” or “reverse” chargebacks.

		
	6.	
    CREDITS AND REBILLS:

		
	 	
     NMC Distribution Center shall submit simultaneously to
    Amgen the credits and their associated rebills within sixty
    (60) calendar days after NMC Distribution Center rebills a
    Customer.

		
	7.	
    CONTRACT ELIGIBILITY:

		
	 	
     Claims will only be honored for sales made in accordance with
    the Bid Award Notifications sent by Amgen to
    NMC Distribution Center. A facility may only participate on
    one (1) contract for each product at any given time. An
    individual contract will take precedence over any group
    purchasing organization contract of which the facility may be a
    part.

		
	8.	
    AUDIT:

		
	 	
     Amgen shall have access to all information necessary to verify
    chargeback claims.

		
	9.	
    DEDUCTIONS:

		
	 	
     Deductions of chargeback claims are not permitted unless
    supported with a valid credit memoranda from Amgen. Amgen’s
    Chargeback Policy conforms with the guidelines set by the
    Healthcare Distribution Management Association. Amgen reserves
    the right to modify its Chargeback Policy upon notice to NMC
    pursuant to Section 8.12 in the Agreement.

18

 

Article Two

Product Return Policy

AUTHORIZATION:

     
Contact Amgen Customer Service Department at 800-282-6436 for
proper instructions for Amgen Products.

RETURNABLE ITEMS:

			
	 	• 	
    Unused partials or full pack quantities with less than one year
    post expiration date.
	 
	 	• 	
    Product received in error or damaged in transit.

NON-REFUNDABLE ITEMS:

     
Although all products may be returned, no credit will be issued
for:

			
	 	• 	
    Product twelve (12) months or more post expiration date.
	 
	 	• 	
    Product destroyed or damaged due to improper storage, heat,
    cold, water, or smoke, left unrefrigerated or other conditions
    beyond the control of Amgen.
	 
	 	• 	
    Product destroyed or losses suffered in a natural disaster
    (flood, hurricane, tornado, etc.).
	 
	 	• 	
    Product obtained other than through normal channels of
    distribution.
	 
	 	• 	
    Product that is in unsaleable condition through no fault of
    Amgen.
	 
	 	• 	
    Product shipped as a no charge item.
	 
	 	• 	
    Unauthorized excess stock.

TRANSPORTATION CHARGES:

			
	 	• 	
    Prepaid by customer

TERMS OF RETURN POLICY:

			
	 	• 	
    Credit if applicable for outdated Product, will be based on
    then-current WAC less ten percent (10%).
	 
	 	• 	
    Credit for indirect customers for outdated product, will be
    issued in the form of a check by Capital Returns Inc. on behalf
    of Amgen.
	 
	 	• 	
    Credit for direct customers for outdated product, will be issued
    by Amgen in the form of a credit invoice.
	 
	 	• 	
    Amgen will not be responsible for any charges associated with
    third party return processors.
	 
	 	• 	
    No credit for shipping, handling and return processing fees.
	 
	 	• 	
    Product ordered or received in error must be reported within
    fifteen (15) business days of Product receipt.
	 
	 	• 	
    Pre-deductions from invoices are not allowed.
	 
	 	• 	
    All items are subject to credit approval by Amgen Customer
    Service.

Third Party Returns Processors:

			
	 	• 	
    For all outdated Product, please forward return with detail
    manifest directly to:

Capital Returns, Inc.

Attn: Amgen Return Goods

6101 North 64th Street

Milwaukee, WI 53218

19

 

COMPANY DISCLAIMER:

			
	 	• 	
    Products returned are subject to Amgen’s and or Capital
    Returns’ evaluation at the time of receipt for final count
    and inspection.
	 
	 	• 	
    Amgen may, with notice to Wholesaler in its sole discretion,
    make exceptions, changes and/or modifications to the Returned
    Goods Policy.

20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}]]